hB101.37 (humanized anti-BAMBI mAb)
Psoriatic Arthritis (PsA) / Psoriasis
Pre-clinicalActive
Key Facts
About Inhibitec
Inhibitec is a private, preclinical-stage biotech spin-off from the University of Cantabria and the Spanish National Research Council (CSIC). The company is advancing a first-in-class, humanized monoclonal antibody (hB101.37) that inhibits BAMBI, a key regulator of CD4 T-cell differentiation. This approach aims to simultaneously reduce pro-inflammatory Th17 cells and enhance regulatory T cells (Tregs), offering a novel therapeutic strategy for psoriatic arthritis and related conditions. The company is backed by national grants, international recognition from the National Psoriasis Foundation, and holds an exclusive license to the foundational patent.
View full company profile